Quantification of nicotinic acetylcholine receptors in human brain using [123I]5-I-A-85380 SPET
β Scribed by Masahiro Fujita; Masanori Ichise; ChristopherH. Dyck; SamiS. Zoghbi; Gilles Tamagnan; AlexeyG. Mukhin; Ali Bozkurt; Nicholas Seneca; Dnyanesh Tipre; ChristopherC. DeNucci; Hidehiro Iida; D.Bruce Vaupel; AndrewG. Horti; AndreiO. Koren; AlaneS. Kimes; EdytheD. London; JohnP. Seibyl; RonaldM. Baldwin; RobertB. Innis
- Publisher
- Springer
- Year
- 2003
- Tongue
- English
- Weight
- 314 KB
- Volume
- 30
- Category
- Article
- ISSN
- 0340-6997
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract In order to image nAChR density __in vivo__ in humans, [5β^123^I]βiodoβ3β[2(S)β2βazetidinylmethoxy]pyridine ([5β^123^I]A85380) has been developed as a SPECT imaging tracer. This article outlines the radiochemical synthesis, __in vitro__ validation in human postβmortem tissue and some in
Tomographic imaging of central nicotinic acetylcholine receptors (nAChRs) via single photon emission computed tomography (SPECT) has been hampered by the lack of a radioligand with suitable in vivo binding characteristics. Therefore, a novel analog of epibatidine, (6)-exo-2-(2-iodo-5-pyridyl)-7-azab
The in vivo regional distribution and pharmacological profile of a novel iodinated phenylpiperazine derivative, [12311p-MPPI (4-(2'-methoxy-)phenyl-l-[2'-(N-2"pyridinyl)-p-iodobenzamido-Iethyl-piperazine), in the rat brain were evaluated for use as a potential in vivo imaging agent for 5-HTlA recept